Hidrasec

Hidrasec is an oral antidiarrheal medication that contains the active ingredient racecadotril, an enkephalinase inhibitor. Marketed in the European Union, Hidrasec is supplied as a tablet (strength not specified) designed for systemic absorption through the gastrointestinal tract. The drug belongs to the therapeutic class of antidiarrheals and works by modulating intestinal secretions, offering a non‑opioid option for managing acute watery diarrhea in both adults and children.

Hidrasec is indicated for the symptomatic treatment of acute watery diarrhea in clinical practice.

- Adults experiencing acute watery diarrhea, typically lasting less than 48 hours. - Children with acute watery diarrhea, including infants, when oral rehydration is feasible. - Use as an adjunct to oral rehydration therapy to reduce stool output. - Preferred when opioid‑based antidiarrheals are unsuitable due to contraindications or side‑effect concerns. - Short‑term management of diarrhea associated with viral or bacterial gastroenteritis. - Situations where rapid reduction of fluid loss is clinically important, such as in dehydration‑prone patients.

Adverse reactions reported with Hidrasec are generally mild and transient, but rare serious events have been described in clinical observations.

Common: - Nausea or mild stomach discomfort, usually occurring shortly after the first dose. - Headache, generally low‑intensity and transient. - Dizziness or light‑headedness, often resolved without intervention. - Transient abdominal cramps or mild colicky pain. - Flatulence or increased intestinal gas. - Mild constipation, typically self‑limited. - Altered taste sensation, such as a metallic or bitter after‑taste.

Serious: - Severe allergic reaction (anaphylaxis, rash, swelling of face or throat) that may require emergency treatment. - Persistent vomiting or diarrhea despite therapy, leading to worsening dehydration. - Severe abdominal pain requiring medical evaluation, possibly indicating complications. - Rare elevation of liver enzymes (hepatic transaminases) observed in laboratory monitoring.

When prescribing Hidrasec, clinicians should consider several precautionary factors to ensure safe use.

- Assess hydration status and continue oral rehydration therapy alongside Hidrasec. - Use with caution in patients with known hypersensitivity to racecadotril or excipients. - Limited safety data in pregnancy; avoid unless benefit outweighs potential risk. - Not recommended for chronic diarrhea or inflammatory bowel disease without further evaluation. - Monitor for signs of allergic reaction, especially after the first dose. - Adjust use in severe renal impairment only under medical supervision.

Potential drug interactions with Hidrasec are limited, but certain combinations warrant attention.

Avoid: - Concomitant use with potent enkephalinase inhibitors that may amplify enkephalin levels, increasing risk of hypotension. - Co‑administration with drugs that significantly alter gastrointestinal pH, which could affect racecadotril absorption.

Use with caution: - Antidiarrheal agents containing opioids (e.g., loperamide) – additive effect on gut motility. - Antihypertensive medications – monitor blood pressure as enkephalin accumulation may have modest vasodilatory effects. - Diuretics – assess fluid balance, especially in dehydrated patients. - Antacids containing aluminum or magnesium – may reduce oral bioavailability of racecadotril.